As well as several novel medicines approvals decisions announced on Friday, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) also recommended several extensions of indications for already marketed drug. A final decision regarding the approvals is expected from the European Commission in the near future.
Among these, the CHMP has adopted a positive opinion recommending approval of Keytruda (pembrolizumab), Merck & Co’s (NYSE: MRK) blockbuster anti-PD-1 therapy, in combination with chemotherapy, with or without bevacizumab (the Keytruda regimen), for the treatment of persistent, recurrent or metastatic cervical cancer in adults whose tumors express PD-L1 (Combined Positive Score [CPS] ≥1).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze